Atara Biotherapeutics, Inc. reports results for the quarter ended June 30 - Earnings Summary

Atara Biotherapeutics

12/08/2026 21:59

Atara Biotherapeutics, Inc. ATRA.OQ reported a quarterly adjusted loss of 32 cents​​ per share for the quarter ended June 30, lower than the same quarter last year, when the company reported EPS of 19 cents.  The mean expectation of four analysts for the quarter was for a loss of 31 cents per share. Wall Street expected results to range from -35 cents to -28 cents per share.
Revenue fell 96.4% to $630.00 thousand from a year ago; analysts expected $366.67 thousand. 
Atara Biotherapeutics, Inc.'s reported EPS for the quarter was a loss of 32 cents​.
The company reported a quarterly loss of $4.83 million.
Atara Biotherapeutics, Inc. shares had fallen by 22.1% this quarter and lost 50.6% so far this year.
FORECAST CHANGES
The mean earnings estimate of analysts had risen by about 6% in the last three months.​ 
In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.
RECOMMENDATIONS
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy" 
Wall Street's median 12-month price target for Atara Biotherapeutics, Inc. is $13.00, about 31.2% above its last closing price of $8.94
This summary was machine generated from LSEG data August 12 at 08:59 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
QUARTER ENDING
ESTIMATE 
ACTUAL
BEAT, MET, MISSED
Jun. 30 2026 
-0.31
-0.32
Missed
Mar. 31 2026 
-0.40
-0.29
Beat
Dec. 31 2025 
-0.17
-0.25
Missed
Sep. 30 2025 
-0.86
-0.32
Beat